PLANO, TX / ACCESS Newswire / November 5, 2025 / BGSF, Inc. (NYSE:BGSF), a growing provider of workforce solutions for the specialized property management industry, today announces that it will delay the release of its fiscal 2025 third quarter results until Friday, November 7, 2025 pre-market, and then management will host its live earnings conference call and webcast at 9:00 am ET on the same day.
The delay in reporting BGSF’s third quarter 2025 earnings is due to additional time required to finalize the accounting for the sale of the Professional division, including its treatment within discontinued and continuing operations.
Interested participants may dial 1-888-506-0062 (Toll-Free) or 1-973-528-0011 (International) and ask for the BGSF call. The live webcast is accessible from the investor relations section of the Company’s website at https://investor.bgsf.com/events-and-presentations/default.aspx.
About BGSF BGSF provides best-in-class property management resources and solutions to growing apartment and luxury communities, as well as commercial properties, and was awarded Supplier Company of the Year by the National Apartment Association in recent years. Through its exclusive and semi-exclusive agreements with some of the largest property management companies in North America, BGSF offers differentiated advantages to clients, including trained talent and unique technological platforms that maximize efficiencies in the growing residential and commercial leased property industries. For more information on the Company and its services, please visit its website at www.bgsf.com.
CONTACT: Steven Hooser or Sandy Martin Three Part Advisors ir@bgsf.com 214.872.2710 or 214.616.2207
SUNNYVALE, CA / ACCESS Newswire / November 5, 2025 / SierraCol Energy has achieved the prestigious OGMP 2.0 Gold Standard from the United Nations Environment Programme’s International Methane Emissions Observatory (UNEP-IMEO), underscoring its position as a regional leader in transparent, cost-effective methane management.
SierraCol Insight M Flyover Insight M Methane Collection Flights over Caño Limón, one of Colombia’s largest fields
In only two years since joining OGMP 2.0, SierraCol reached Level 5 reporting across its material assets and met all criteria for the Gold Standard – a distinction recognizing companies with the highest quality measurement-based methane data and verified mitigation performance. According to UNEP’s An Eye on Methane 2025 report, “SierraCol and Kiwetinohk reported assets at Level 5 in their second year of membership”, achieving the Gold Standard within two years of joining the initiative.
SierraCol’s achievement represents not just an environmental milestone but also a demonstration of leadership in operational excellence and responsible growth. The company’s discipline in setting NPV-positive decarbonization initiatives – each with a payback in the short term – reinforces that emissions reduction can create measurable economic value and align with business performance.
“Reliable methane measurements drive high-impact decarbonization – guiding investment toward projects that deliver quick, measurable, and lasting value” said Juan Carlos Lopez Ballen, Head of Decarbonization and water footprint, at SierraCol Energy.
SierraCol’s rapid progress builds on its early recognition in the An Eye on Methane 2024 report, where UNEP highlighted its “best-in-class implementation plan” among first-year participants – including robust reduction targets, comprehensive mitigation plans, and a clear roadmap for Level 4 and Level 5 reporting across material assets.
To achieve this year’s milestone, SierraCol partnered with Insight M as its technical solutions provider for Level 5 measurement campaigns. Insight M employed integrated, measurement-based methodologies – combining site-level screening and source-level quantification – to reconcile methane emissions across diverse field conditions. This approach enhanced the accuracy and reliability of SierraCol’s OGMP 2.0 data and provided the measurement integrity necessary for UNEP’s Gold Standard verification.
“SierraCol’s success demonstrates how rigorous measurement and innovative technical design can transform methane management from a compliance task into a leadership advantage,” said David Bercovich, Chief Executive Officer at Insight M. “Our collaboration shows that strong data and practical implementation can deliver both climate impact and economic performance.”
SierraCol’s advancement exemplifies how credible data, reliable measurement, and strong governance can accelerate progress toward measurable methane reduction. Together, SierraCol, Insight M, and OGMP 2.0 are helping define what meaningful, verifiable methane leadership looks like across the energy sector in Latin America.
About Insight M
Founded in 2014, Insight M is a methane emissions management company helping oil and gas operators reduce emissions and improve efficiency. The world’s safest Leak Detection and Repair (LDAR) solution, Insight M delivers pragmatic methane solutions that maximize profits and emissions reductions while minimizing the time operations teams need to spend in the field.. To date, it has saved customers over $500 million in gas value and prevented 140 billion cubic feet of methane from entering the atmosphere.
Contact Information
Charlie Feinerman Sr. Director, Brand & Marketing charlie@insightm.com 8565778565
Florida-Based Keller Swan Joins TopDog Law to Strengthen Courtroom Expertise Across the Southeast.
SCOTTSDALE, AZ / ACCESS Newswire / November 5, 2025 / Helm Law Group, LLC, d/b/a TopDog Law, a national personal injury law firm, has acquired Keller Swan Injury Attorneys, a respected trial firm headquartered in Jupiter, Florida, practicing across Florida, Georgia, Tennessee, Arkansas, Mississippi, and Arizona. The move expands TopDog Law’s in-house trial capabilities and marks a major milestone as the firm continues building one of the most recognized and formidable brands in personal injury law.
TopDog Law Logo
Founded by attorney James Helm, TopDog Law has been recognized by Inc. 5000 as the fastest-growing personal injury law firm in the United States in 2025, driven by its data-driven marketing, technology-enabled case management, and relentless focus on lient results. The firm has built a national reputation for helping accident victims secure justice while redefining how personal injury law is practiced at scale.
“We are excited to take this next step in the evolution of TopDog Law in becoming not only one of the best-known personal injury brands in America but also a highly formidable trial firm,” said James Helm, Founder and CEO of TopDog Law. “We wanted our first law firm acquisition to be a firm that isn’t afraid to file suit and take cases to trial. We will continue to add other trial lawyers that match this philosophy in our effort to build out a world-class trial firm within TopDog Law”.
This acquisition will build upon TopDog Law’s strong team of attorneys and co-counsel firms across the country. “We value our law firm partnerships across America that have helped us get to this point,” Helm added. “As we build out a formidable trial firm, hose relationships will remain a core part of how TopDog Law continues to grow and serve clients nationwide.”
Chris Keller and Blake Swan will join TopDog Law as Managing Partners. Both are proven litigators with extensive trial experience and a history of securing strong results for injured clients. They are eager to leverage TopDog Law’s case acquisition engine and financial resources to litigate complex injury cases and fight to get clients the compensation they deserve. “We’re thrilled to join forces with TopDog Law,” said Chris Keller, Managing Partner at Keller Swan Injury Attorneys. “James and his team have built an incredible foundation for growth, and we’re excited to bring our trial experience to TopDog Law, where we will continue fighting for clients in and out of the courtroom.”
“This partnership is an incredible opportunity for our entire team,” said Blake Swan, Managing Partner at Keller Swan Injury Attorneys. “We’ve built a culture of relentless advocacy, and now, with TopDog Law’s national platform and resources, our attorneys and staff have the opportunity to grow, take on larger cases, and make an even greater impact for our clients. We’re proud of what we’ve accomplished and energized by what lies ahead.” The acquisition strengthens TopDog Law’s presence across key Southeastern markets and establishes a foundation for the continued growth of its trial operations nationwide.
About TopDog Law
Founded by James Helm, TopDog Law is a national personal injury law firm dedicated to helping accident victims get the justice they deserve. Recognized by Inc. 5000 as the fastest-growing personal injury law firm in the United States in 2025, TopDog Law combines data-driven marketing, technology innovation, and exceptional client advocacy to deliver industry-leading results. The firm is headquartered in Scottsdale, Arizona, with offices and affiliated attorneys across most of the country.
About Keller Swan Injury Attorneys Headquartered in Jupiter, Florida, Keller Swan Injury Attorneys is a leading personal injury law firm with 12 attorneys and more than 80 staff members, representing clients across Florida, Georgia, Tennessee, Arkansas, Mississippi, and Arizona. The firm is known for its client-centered approach, skilled trial lawyers, and successful outcomes across motor vehicle, premises liability, and catastrophic injury cases.
LAFAYETTE, LA / ACCESS Newswire / November 5, 2025 / Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced today that it has reported its financial results for the three and nine months ended September 30, 2025.
Operational highlights (all dollar amounts are USD):
Net revenues for the quarter ended September 30, 2025 were $71.9 million, setting a Company record, representing an increase of $13.9 million, or 24.0%, over net revenues reported for the comparable quarter ended September 30, 2024.
Net income attributable to Viemed for the quarter ended September 30, 2025 totaled $3.5 million, or $0.09 per diluted share.
Adjusted EBITDA for the quarter ended September 30, 2025 totaled $16.1 million, a 15.5% increase as compared to the quarter ended September 30, 2024.
Net cash provided by operating activities totaled $18.4 million for the quarter and $48.5 million for the trailing twelve months ended September 30, 2025. Free cash flow totaled $12.4 million for the quarter and $23.3 million for the trailing twelve months ended September 30, 2025.
On July 1, 2025, Viemed closed on the strategic acquisition of Lehan’s Medical Equipment (“Lehan”). The results of Lehan’s operations have been included in the consolidated financial statements since the date of acquisition and were immediately accretive to net income and earnings per share.
During the third quarter of 2025, the Company repurchased and cancelled 1,706,380 common shares under its share repurchase program at a cost of $11.4 million, representing an average buyback price of $6.68 per share.
The Company increased its ventilator patient count to 12,372 as of September 30, 2025, an increase of 8.8% over September 30, 2024, and a 1.8% sequential increase from June 30, 2025.
The Company increased its PAP therapy patient count to 31,891 as of September 30, 2025, an increase of 63.7% over September 30, 2024, and a 21.4% sequential increase from June 30, 2025. The Company’s sleep resupply patient count was 33,518 as of September 30, 2025, an increase of 51.4% over September 30, 2024, and a 32.8% sequential increase from June 30, 2025.
As of September 30, 2025, the Company maintains a strong cash balance of $11.1 million and an overall working capital balance of $5.8 million. Long term debt as of September 30, 2025 amounted to $19.6 million and the Company has $38 million available under existing credit facilities.
Full Year 2025 Guidance (all dollar amounts are USD):
The Company is updating its financial guidance for the year ending December 31, 2025:
Net Revenue: Now expected to be in the range of $271 million to $273 million, compared to the previous guidance of $271 million to $277 million.
Adjusted EBITDA: Now expected to be in the range of $60 million to $62 million, compared to the previous guidance of $59 million to $62 million.
The narrowing of the range primarily reflects the passage of time and increased visibility into the remainder of the year, as the forecast period shortens. This outlook excludes the impact of any potential future acquisitions or other strategic transactions. For additional information regarding non-GAAP financial measures, please refer to the “Use of Non-GAAP Financial Information and Financial Guidance” section below.
Casey Hoyt, Viemed’s CEO, commented, “We delivered another outstanding quarter marked by strong execution and sustained expansion of our patient base across every major service line. Our disciplined approach to capital deployment was demonstrated through the full completion of our 2025 share repurchase program, while the acquisition of Lehan’s Medical Equipment further enhanced our market presence and diversified our service capabilities. Both initiatives were accretive to earnings per share and reflect our unwavering commitment to creating long-term shareholder value while improving patient outcomes across the communities we serve.”
“In addition, our strong liquidity and consistent free cash flow generation provide the flexibility to pursue strategic growth opportunities and return capital to shareholders, while preserving the financial strength that underpins our long-term success.”
Conference Call Details
The Company will host a conference call to discuss third quarter results on Thursday, November 6, 2025, at 11:00 a.m. ET.
Interested parties may participate in the call by dialing:
Following the conclusion of the call, an audio recording and transcript of the call can be accessed on the Company’s website.
ABOUT VIEMED HEALTHCARE, INC.
Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at www.viemed.com.
Certain statements contained in this press release may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company’s net revenue and Adjusted EBITDA guidance for 2025, the anticipated synergies and other benefits of the acquisition of Lehan’s Medical Equipment, future capital allocation priorities, liquidity position, free cash flow generation, and strategic growth opportunities, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which we operate; significant capital requirements and operating risks that we may be subject to; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns, as well as other general economic, market and business conditions; and other factors beyond our control; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedar.com. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.
Use of Non-GAAP Financial Information and Financial Guidance
This press release includes references to financial measures that are calculated and presented using methodologies other than those in accordance with generally accepted accounting principles in the United States (“GAAP”), including Adjusted EBITDA and free cash flow. Any non-GAAP financial measures presented herein are intended to supplement, and not to be considered superior to or as a substitute for, the Company’s consolidated financial statements prepared in accordance with GAAP. These non-GAAP financial measures exclude significant expense and income items required by GAAP, and are subject to inherent limitations, including the exercise of judgment by management regarding which items to exclude or include. Non-GAAP measures presented herein may not be comparable to similarly titled measures presented by other companies. The reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are included in the tables accompanying this release.
This press release contains non-GAAP financial guidance. There is no reliable or reasonably estimable comparable GAAP measure for the Company’s non-GAAP financial guidance because the Company is not able to reliably predict the impact of certain items that typically have one or more of the following characteristics: highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. As a result, reconciliation of the non-GAAP financial guidance to the most directly comparable GAAP measure is not available without unreasonable effort. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on the Company’s future GAAP results. The Company’s financial guidance in this press release excludes the impact of potential future strategic acquisitions and any items that have not yet been identified or quantified. This guidance is subject to risks and uncertainties inherent in all forward-looking statements, as outlined above.
VIEMED HEALTHCARE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Expressed in thousands of U.S. Dollars, except share amounts) (Unaudited)
At
September 30, 2025
At
December 31, 2024
ASSETS
Current assets
Cash and cash equivalents
$
11,123
$
17,540
Accounts receivable, net
27,414
24,911
Inventory
5,269
4,320
Income tax receivable
1,913
–
Prepaid expenses and other assets
4,265
6,109
Total current assets
$
49,984
$
52,880
Long-term assets
Property and equipment, net
80,512
76,279
Finance lease right-of-use assets
–
50
Operating lease right-of-use assets
3,589
2,831
Equity investments
2,794
2,794
Deferred tax asset
5,669
8,398
Identifiable intangibles, net
1,348
848
Goodwill
58,464
32,989
Total long-term assets
$
152,376
$
124,189
TOTAL ASSETS
$
202,360
$
177,069
LIABILITIES
Current liabilities
Trade payables
$
8,670
$
5,322
Deferred revenue
7,810
6,694
Income taxes payable
–
3,883
Accrued liabilities
25,007
20,157
Finance lease liabilities, current portion
–
50
Operating lease liabilities, current portion
1,149
811
Current portion of long-term debt
1,554
409
Total current liabilities
$
44,190
$
37,326
Long-term liabilities
Accrued liabilities
680
846
Operating lease liabilities, less current portion
2,410
2,007
Long-term debt
19,585
3,589
Total long-term liabilities
$
22,675
$
6,442
TOTAL LIABILITIES
$
66,865
$
43,768
Commitments and Contingencies
–
–
SHAREHOLDERS’ EQUITY
Common stock – No par value: unlimited authorized; 38,017,907 and 39,132,897 issued and outstanding as of September 30, 2025 and December 31, 2024, respectively
16,901
23,365
Additional paid-in capital
19,453
18,337
Retained earnings
97,254
89,691
TOTAL VIEMED HEALTHCARE, INC.’S SHAREHOLDERS’ EQUITY
$
133,608
$
131,393
Noncontrolling interest in subsidiary
1,887
1,908
TOTAL SHAREHOLDERS’ EQUITY
135,495
133,301
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
$
202,360
$
177,069
VIEMED HEALTHCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Expressed in thousands of U.S. Dollars, except outstanding shares and per share amounts) (Unaudited)
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
2025
2024
Revenue
$
71,914
$
58,004
$
194,099
$
163,562
Cost of revenue
30,569
23,633
82,744
66,497
Gross profit
$
41,345
$
34,371
$
111,355
$
97,065
Operating expenses
Selling, general and administrative
31,919
26,671
89,147
77,988
Research and development
775
757
2,419
2,265
Stock-based compensation
2,180
1,712
6,832
4,764
Depreciation and amortization
397
348
1,098
1,140
Loss (gain) on disposal of property and equipment
476
(469
)
(2,528
)
(801
)
Other expense (income), net
(44
)
(276
)
(191
)
261
Income from operations
$
5,642
$
5,628
$
14,578
$
11,448
Non-operating income and expenses
Income (loss) from investments
–
96
–
(954
)
Interest expense, net
(507
)
(225
)
(818
)
(629
)
Net income before taxes
5,135
5,499
13,760
9,865
Provision for income taxes
1,535
1,594
4,200
2,880
Net income
$
3,600
$
3,905
$
9,560
$
6,985
Net income attributable to noncontrolling interest
87
27
265
36
Net income attributable to Viemed Healthcare, Inc.
$
3,513
$
3,878
$
9,295
$
6,949
Net income per share
Basic
$
0.09
$
0.10
$
0.24
$
0.18
Diluted
$
0.09
$
0.10
$
0.23
$
0.17
Weighted average number of common shares outstanding:
Basic
38,638,660
38,870,823
39,190,666
38,803,887
Diluted
40,495,761
40,779,414
41,086,178
40,702,001
VIEMED HEALTHCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Expressed in thousands of U.S. Dollars) (Unaudited)
Nine Months Ended September 30,
2025
2024
Cash flows from operating activities
Net income
$
9,560
$
6,985
Adjustments for:
Depreciation and amortization
21,043
19,002
Stock-based compensation expense
6,832
4,764
Distributions of earnings received from equity method investments
–
147
Income from equity method investments
–
(261
)
Loss from debt investment
–
1,344
Gain on disposal of property and equipment
(2,528
)
(801
)
Amortization of deferred financing costs
121
135
Deferred income tax expense (benefit)
2,729
(3,507
)
Changes in working capital:
Accounts receivable, net
(670
)
(8,213
)
Inventory
(163
)
583
Prepaid expenses and other assets
(626
)
340
Trade payables
767
747
Deferred revenue
622
489
Accrued liabilities
1,584
2,424
Income tax payable/receivable
(5,796
)
(76
)
Net cash provided by operating activities
$
33,475
$
24,102
Cash flows from investing activities
Purchase of property and equipment
(31,248
)
(25,942
)
Cash paid for acquisitions, net of cash acquired
(26,332
)
(2,999
)
Proceeds from sale of property and equipment
15,026
7,440
Net cash used in investing activities
$
(42,554
)
$
(21,501
)
Cash flows from financing activities
Proceeds from exercise of options
1,439
416
Proceeds from term notes
9,000
–
Principal payments on term notes
(484
)
(954
)
Proceeds from revolving credit facilities
13,000
3,000
Payments on revolving credit facilities
(5,000
)
(5,000
)
Payments for debt issuance costs
–
(171
)
Shares redeemed to pay income tax
(1,732
)
(1,065
)
Shares repurchased under the share repurchase program
(13,225
)
–
Repayments of finance lease liabilities
(50
)
(319
)
Distributions to non-controlling interest
(286
)
–
Net cash provided by (used in) financing activities
$
2,662
$
(4,093
)
Net decrease in cash and cash equivalents
(6,417
)
(1,492
)
Cash and cash equivalents at beginning of year
17,540
12,839
Cash and cash equivalents at end of period
$
11,123
$
11,347
Supplemental disclosures of cash flow information
Cash paid during the period for interest
$
587
$
745
Cash paid during the period for income taxes, net of refunds
$
7,267
$
6,416
Supplemental disclosures of non-cash transactions
Equipment and other fixed asset purchases payable at end of period
$
4,774
$
2,854
Equipment sales receivable at end of period
$
–
$
1,683
Reconciliation from GAAP Net Income to Non-GAAP Adjusted EBITDA
This press release refers to “Adjusted EBITDA”, which is a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). Adjusted EBITDA should be considered in addition to, not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Management believes Adjusted EBITDA provides helpful information with respect to the Company’s operating performance as viewed by management, including a view of the Company’s business that is not dependent on the impact of the Company’s capitalization structure and items that are not part of the Company’s day-to-day operations. Management uses Adjusted EBITDA (i) to compare the Company’s operating performance on a consistent basis, (ii) to calculate incentive compensation for the Company’s employees, (iii) for planning purposes, including the preparation of the Company’s internal annual operating budget, and (iv) to evaluate the performance and effectiveness of the Company’s operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating the Company’s operating performance in the same manner as management. Adjusted EBITDA is not a measurement of the Company’s financial performance under GAAP and should not be considered as an alternative to revenue or net income, as applicable, or any other performance measures derived in accordance with GAAP. Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of the Company’s operating results as reported under GAAP. Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters the Company considers not to be indicative of ongoing operations; and other companies in the Company’s industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure. In calculating Adjusted EBITDA, certain items (mostly non-cash) are excluded from net income attributable to Viemed Healthcare, Inc., including depreciation and amortization of capitalized assets, net interest expense, stock based compensation, transaction costs, impairment of assets, and taxes.
The following table is a reconciliation of net income attributable to Viemed Healthcare, Inc., the most directly comparable GAAP measure, to Adjusted EBITDA, on a historical basis for the periods indicated:
(Expressed in thousands of U.S. Dollars; unaudited)
For the quarter ended
September 30, 2025
June 30, 2025
March 31, 2025
December 31, 2024
September 30, 2024
June 30, 2024
March 31, 2024
December 31, 2023
Net income attributable to Viemed Healthcare, Inc.
$
3,513
$
3,157
$
2,625
$
4,316
$
3,878
$
1,468
$
1,603
$
3,477
Add back:
Depreciation & amortization
7,539
6,891
6,613
6,366
6,408
6,309
6,285
5,918
Interest expense, net
507
132
179
147
225
254
150
256
Stock-based compensation(a)
2,180
2,341
2,311
1,521
1,712
1,620
1,432
1,534
Transaction costs(b)
847
53
85
11
12
221
110
61
Impairment of assets(c)
–
–
–
–
125
2,173
–
–
Income tax expense
1,535
1,713
952
1,881
1,594
768
518
1,599
Adjusted EBITDA
$
16,121
$
14,287
$
12,765
$
14,242
$
13,954
$
12,813
$
10,098
$
12,845
(a) Represents non-cash, equity-based compensation expense associated with option and RSU awards. (b) Represents transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions. (c) Represents impairments of the fair value of investment and litigation-related assets.
Reconciliation from GAAP Net Cash Provided by Operating Activities to Non-GAAP Free Cash Flow
This press release refers to “free cash flow” which is a non-GAAP financial measure that does not have a standardized meaning prescribed by GAAP. Free cash flow should be considered in addition to, and not as a substitute for, net cash provided by operating activities as reported under GAAP. The Company’s presentation of this financial measure may not be comparable to similarly titled measures used by other companies.
We present non-GAAP free cash flow for the current quarter and trailing twelve months (TTM) as a supplemental liquidity measure. Management believes free cash flow provides investors with useful insight into the company’s ability to generate cash, fund growth initiatives, and return capital to shareholders. Free cash flow is defined as net cash provided by operating activities, as reported under GAAP, less net capital expenditures (Net CAPEX). Net CAPEX is calculated as purchases of property and equipment minus proceeds from the sale of property and equipment in order to reflect both outflows and inflows associated with routine equipment turnover. Trailing twelve months (TTM) free cash flow is calculated by aggregating the last four quarters, each calculated using the methodology described above.
The following table is a reconciliation of net cash provided by operating activities, the most directly comparable GAAP measure, to free cash flow, on a historical basis for the periods indicated:
(Expressed in thousands of U.S. Dollars; unaudited)
BOCA RATON, FL / ACCESS Newswire / November 4, 2025 / Newsmax Inc. (NYSE:NMAX) (“Newsmax” or the “Company”) today announced that management, including CEO Christopher Ruddy, will attend the RBC Capital Markets Global Technology, Internet, Media & Telecommunications Conference being held in New York City from November 18-19, 2025.
Management and Mr. Ruddy will be available for 1×1 meetings throughout the conference. For more information, or to schedule a meeting with management, please contact your RBC Capital Markets representative.
About Newsmax Newsmax Inc. is listed on the NYSE (NMAX) and operates, through Newsmax Broadcasting LLC, one of the nation’s leading news outlets, the Newsmax channel. The fourth highest-rated network is carried on all major pay TV providers. Newsmax’s media properties reach more than 40 million Americans regularly through Newsmax TV, the Newsmax App, its popular website Newsmax.com, and publications such as Newsmax Magazine. Through its social media accounts, Newsmax reaches more than 20 million combined followers. Reuters Institute says Newsmax is one of the top U.S. news brands and Forbes has called Newsmax “a news powerhouse.”
BASE SHELF PROSPECTUSES ARE ACCESSIBLE, AND PROSPECTUS SUPPLEMENTS WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR
TORONTO, ON / ACCESS Newswire / November 4, 2025 / Electrovaya Inc. (“Electrovaya” or the “Company“) (NASDAQ:ELVA)(TSX:ELVA), a leading lithium-ion battery technology and manufacturing company, is pleased to announce that the Company is commencing an underwritten public offering (the “Offering“) of its common shares (the “Common Shares“). The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of Common Shares at the public offering price. All of the Common Shares are being offered by the Company.
The Common Shares will be offered in the United States pursuant to a shelf registration statement (including a prospectus supplement thereto) previously filed with and declared effective by the Securities and Exchange Commission (the “SEC“) on September 25, 2024 (the “U.S. Base Shelf Prospectus“) in accordance with the Multijurisdictional Disclosure System established between Canada and the United States, and will be qualified for distribution in the provinces and territories of Canada by way of a prospectus supplement to the Company’s base shelf prospectus dated September 17, 2024 (the “Canada Base Shelf Prospectus“), provided that no securities will be sold in the Province of Québec.
Oppenheimer & Co. Inc. is acting as sole book-running manager for the proposed Offering. Raymond James Ltd. is acting as the lead manager for the proposed Offering.
The Company intends to use the net proceeds from the Offering to invest in energy as a service, investment in next generation battery and separator research and development and for working capital and general corporate purposes.
The Offering is expected to be priced in the context of the market, with the final terms of the Offering to be determined at the time of pricing. There can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering. The closing of the Offering will be subject to customary closing conditions, including the listing of the Common Shares on the Toronto Stock Exchange (“TSX“) and the Nasdaq Capital Market (“NASDAQ“) and any required approvals of TSX and NASDAQ.
Access to the U.S. Base Shelf Prospectus, the Canada Base Shelf Prospectus, the preliminary prospectus supplement and accompanying prospectus related to the Offering, and any amendments to the documents will be provided in accordance with securities legislation relating to procedures for providing access to a shelf prospectus supplement, a base shelf prospectus and any amendments. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available (within two business days of the date hereof) for free on the SEC’s website at www.sec.gov and the prospectus supplement filed in Canada will be available (within two business days of the date hereof) on the Company’s profile on the SEDAR+ website at www.sedarplus.ca. The Common Shares are offered under the prospectus supplements relating to the offering. An electronic or paper copy of the preliminary prospectus supplement and accompanying prospectus relating to the Offering, when filed, and any amendment to the documents may be obtained without charge from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com and from Raymond James Ltd., Scotia Plaza, 40 King St. W., 54th Floor, Toronto, Ontario M5H 3Y2, Canada, or by telephone at 416-777-7000 or by email at ECM-Syndication@raymondjames.ca. The U.S. Base Shelf Prospectus, the Canada Base Shelf Prospectus and the preliminary prospectus supplement and accompanying prospectus relating to the Offering contain important, detailed information about the Company and the proposed Offering. Prospective investors should read the preliminary prospectus supplement and accompanying prospectus relating to the Offering, and the base shelf prospectus and the other documents the Company has filed before making an investment decision. The final terms of the Offering will be disclosed in a final prospectus supplement to be filed with the SEC and SEDAR+.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, state or jurisdiction.
Investor and Media Contact: Jason Roy VP, Corporate Development and Investor Relations Electrovaya Inc. 905-855-4618 / jroy@electrovaya.com
About Electrovaya Inc.= Electrovaya Inc. (NASDAQ:ELVA)(TSX:ELVA) is a pioneering leader in the global energy transformation, focused on contributing to the prevention of climate change by supplying safe and long-lasting lithium-ion batteries without compromising energy and power. The Company designs, develops and manufactures proprietary lithium-ion batteries, battery systems, and battery- related products for energy storage, clean electric transportation, and other specialized applications. Electrovaya has two operating sites in Canada and a 52-acre site with a 135,000 square foot manufacturing facility in Jamestown New York state for its planned gigafactory. To learn more about how Electrovaya is powering mobility and energy storage, please explore www.electrovaya.com.
Forward-Looking Statements This press release contains forward-looking statements, including statements regarding the intention to complete the Offering and the anticipated use of proceeds from the Offering. Forward-looking statements can generally, but not always, be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements are necessarily based on assumptions, and involve risks and uncertainties, therefore undue reliance should not be placed on such statements. Material assumptions on which forward-looking statements in this news release include assumptions about the ability to profitably market the Common Shares. Material risks and other factors that could cause actual results to differ from any forward-looking statement market conditions and other risks that may be found in the prospectus supplement and base shelf prospectus filed in connection with the Offering, including those risks described under the heading “Risk Factors”, and the documents incorporated by referenced therein. The Company does not undertake any obligation to update publicly or to revise any of the forward looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.
NEW YORK, NY / ACCESS Newswire / November 4, 2025 / Europe’s green economy just got its first real ledger. Not the kind filled with estimates, pledges, or recycled buzzwords, but one written in chemistry, code, and truth. In Valladolid, Spain, SMX (NASDAQ:SMX) and CARTIF have plans to team up to create something far more powerful than another sustainability initiative. They’re intent on minting the next global currency: proof.
This partnership won’t be theoretical: it’s infrastructure. CARTIF, one of Europe’s most respected applied research centers, is evaluating SMX’s molecular “physical-to-digital” technology for direct use in the pilot plants and innovation hubs that shape Spain’s Castilla y León region’s €12.7 billion industrial base. Together, they’re taking the circular economy off the page and into the factory.
Every manufacturer talks about transparency. Few can actually prove it. SMX makes that possible. Its molecular markers attach invisibly to materials at the molecular level, turning plastics, computer hardware, metals, and even liquids into their own witnesses. The data moves with the material, telling its complete life story from production to reuse. No QR codes to fade, no forged certificates. Just truth, secured in chemistry and written to the blockchain.
A New Proving Ground
For CARTIF, the implications are enormous. The center’s research portfolio spans packaging, renewables, construction, automotive, and critical materials. Integrating SMX’s platform means every test, trial, and prototype can now generate real circular data-proof that feeds directly into Europe’s most pressing ESG mandates. From lab to legislation, the results can finally be verified, quantified, and monetized.
That last part matters most. The world doesn’t just need sustainability; it needs sustainability that pays its own way. Proof changes everything. Once circular performance is measured with precision, it can be financed, insured, and traded. SMX’s data can unlock sustainability-linked loans, attract impact investors, and certify recycled content with forensic precision. Environmental integrity becomes a balance-sheet advantage. A verified molecule can be as valuable as a minted coin.
For Europe’s industrial heartland, this is a competitive reset. The continent’s next growth cycle will belong to the companies that can show, not tell. A factory that can prove its recycled content can have lower borrowing costs. A brand that can trace its materials can command higher market trust. A region that can guarantee transparency will attract more capital than one that can only promise it. Valladolid is poised to lead that charge.
A Mission Aligned with Global Intentions
CARTIF’s Deputy General Manager summed it up clearly: “Our mission is to deploy technologies that help our stakeholders meet sustainability goals. SMX’s platform offers exactly the kind of breakthrough capability our clients need to prove and improve circular performance.” Those words mark the divide between two economies-one built on statements, the other on substance.
The SMX-CARTIF partnership signals a shift from compliance to consequence. Instead of meeting minimum standards, companies can now compete on the quality of their proof. Transparency becomes a form of performance, a quantifiable strength that builds both reputation and revenue. In a sense, SMX’s molecular markers have turned trust itself into a tradable asset.
The ripple effect will be hard to overstate. As more sectors adopt molecular tracking-automotive, renewable energy, electronics, construction, and packaging, among others-a network effect begins to emerge. A verified input in Spain could be part of a verified product in Germany and resold in France with full traceability intact. Every link in the chain adds strength to the system. Proof doesn’t weaken when shared; it compounds.
Europe’s Moment to Prove Its Mission is Real
This is the moment Europe’s sustainability narrative becomes measurable. The Green Deal no longer reads like a regulation-it reads like an opportunity. With SMX’s technology embedded inside CARTIF’s ecosystem, Spain isn’t just following policy. It’s defining practice. The continent’s circular-economy intentions now have a real operating system. One that can calculate, confirm, and capitalize on every ounce of verified material that moves through it.
The world once built its wealth on extraction. Now it’s shifting toward regeneration. The difference between those two models is proof: proof that a resource can return, that waste can work again, that every molecule has value left in it. SMX and CARTIF have given Europe the tools to make that shift permanent.
Valladolid may not yet be a household name, but soon it can be known as the birthplace of something bigger than sustainability. It’s where the physical world finally found its digital reflection. And, as importantly, it’s where EU materials gained their own identity, and where circularity became a currency.
About SMX
As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.
Forward-Looking Statements
The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.
The AI-powered platform eliminates manual commission spreadsheets, giving insurers real-time visibility into revenue and agent payouts.
SAN FRANCISCO, CA / ACCESS Newswire / November 5, 2025 / Fintary, the AI-powered revenue growth platform that helps insurance organizations streamline commission and financial operations, today announced it has raised $10M in Series A. The round was led by Infinity Ventures, with participation from Sierra Ventures and other existing investors. This latest investment brings Fintary’s total funding to $12.8M and will accelerate the company’s mission to modernize financial operations across the insurance industry.
Insurance companies face enormous challenges managing complex commission structures – hierarchies, overrides, bonuses, and splits – that are still largely handled through manual spreadsheets. Agencies report spending up to 15 – 40 hours a week on commission processing, reconciliation, and reporting – time that should be spent growing their core business. It’s a time sink that leads to revenue leaks, payout delays, and operational bottlenecks that limit growth.
Fintary transforms this process by automating commission operations end-to-end, giving insurers real-time visibility into profitability and ensuring agents are paid accurately and on time.
The company was founded by Qiyun Cai, one of the few female founders in the space, who experienced these operational challenges firsthand early in her career. “I’ll never forget staying up until 2AM on a Sunday, buried in spreadsheets trying to reconcile commissions,” said Cai, co-founder and CEO of Fintary. “And that’s when I realized it had to stop. The industry deserves better.”
Cai launched Fintary to reimagine how insurance companies manage their most complex financial operations, turning what was once a painful back-office chore into a strategic growth driver. Under her leadership, Fintary has built a fast-growing platform that blends deep insurance expertise with world-class engineering talent from Google, Microsoft, and multiple successful startups.
“Fintary stands out because they understand the insurance world from the inside out,” said Jeremy Jonker, Co-Founder and Managing Partner at Infinity Ventures. “Their platform has processed millions in commissions – they know the pain of chargebacks and hierarchy overrides firsthand. That’s why they’re able to build technology that goes beyond efficiency. Fintary is helping insurers grow faster, operate smarter, and turn financial operations into a competitive advantage.”
Fintary already works with insurance organizations across life & annuity, employee benefits, health, and property & casualty lines. Customers have reduced weeks of manual reconciliation to minutes, improved accuracy and transparency in commission payouts, and increased agent satisfaction and retention.
With this new funding, Fintary will continue scaling its team, expand its product capabilities, and extend its AI-powered platform into broader areas of insurance financial management.
About Fintary
Fintary is an AI-powered revenue growth platform that automates commission processing and financial operations for insurance companies, enabling them to scale efficiently while improving agent satisfaction and loyalty. Founded by Qiyun Cai, Yu Chen, and Michael Lee, Fintary is building the infrastructure that will fuel the next generation of people-powered businesses. Learn more at https://www.fintary.com/.
NEW YORK, NY / ACCESS Newswire / November 5, 2025 / Every industry eventually faces its accountability moment. For decades, companies could talk about sustainability, traceability, and circularity without ever proving it. But that era is closing fast. The world’s most influential institutions are no longer chasing sustainability reports. They are chasing evidence.
That shift has created a once-in-a-generation opening for a company built entirely on proof. SMX (NASDAQ:SMX) has spent years developing molecular marking and digital passport systems that let materials carry their own history. Today, those quiet breakthroughs are reshaping how nations and industries define value. What began as science in a lab has become the language of global trust.
Building the Framework of Proof
SMX’s rise isn’t driven by buzzwords or hype cycles. It’s built on partnerships that have transformed ideas into infrastructure. Singapore’s A*STAR is working with SMX to develop a national plastics passport system that tracks every molecule from production to reuse. It’s not just about recycling. It’s about assigning a measurable identity to the world’s most persistent materials. When Singapore embeds your technology into a government framework, it means you have graduated from pilot to policy.
In Europe, SMX has found two powerful allies. Spain’s CARTIF brings research and validation muscle, turning theory into verified industrial applications. France’s CETI brings the fashion and textile industry into the conversation, using SMX’s molecular IDs to authenticate fibers, certify recycled content, and give every fabric its own proof of origin. Together, these institutions are proving that verification is not a cost. It’s a currency.
Proof That Pays
The business case for proof is finally clear. Brands and governments no longer want to promise progress. They want to measure it. SMX’s technology lets them do exactly that, embedding trust at the molecular level. When you can verify what something is, where it came from, and how it was made, you can turn compliance into commerce.
In the United States, Tradepro is already showing how that works. Verified recycled plastic bales command higher prices and meet the growing demands of consumer brands that need certified content. That is proof creating profit. At the same time, Austria’s REDWAVE is using SMX markers in its smart sorting systems to separate materials in real time. What used to be a waste stream now becomes a revenue stream.
Even the oldest asset classes are being redefined. Singapore-based Goldstrom is using SMX’s molecular markers to give gold and silver a digital memory. Each bar or coin can now prove its origin and history, turning precious metals into verifiable data assets. Proof has become portable. It moves with the material wherever it goes.
A Global Network Takes Shape
What ties these relationships together is a shared goal: to turn transparency into infrastructure. SMX sits at the center of that network. Each partnership adds new geography, new expertise, and new credibility. Together, they are building a system of record for the physical world, where authenticity can be proven as easily as identity online.
It’s no longer about isolated use cases. It’s about forming the architecture for verified commerce. SMX has positioned itself where governments, industries, and investors intersect. That makes it more than a technology provider. It makes it the foundation of a new economy that runs on evidence rather than promises.
The New Global Standard
What began with molecular markers has evolved into a movement. A*STAR, CARTIF, CETI, Goldstrom, REDWAVE, and Tradepro represent more than partnerships. They represent a global consensus forming around a single idea: proof is no longer optional. It’s the baseline requirement for credibility, finance, and growth.
SMX didn’t create that demand. It anticipated it. The world has reached a point where sustainability can’t be declared; it must be demonstrated. Where provenance can’t be assumed; it must be recorded. And where the companies and agencies that verify truth become the ones that define value.
The proof standard is here, and it speaks a universal language. From Singapore to Spain to France to the United States, the world’s most trusted institutions are building on SMX. Not because it’s fashionable, but because it’s functional. Proof is now infrastructure, and SMX wrote the code that makes it work.
About SMX
As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.
Forward-Looking Statements
The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.
ECG will exhibit in a 10-foot booth, presenting the latest evolution of its Addison Virtual Care Platform – a next-generation solution that provides continuous patient oversight, daily adherence support, and early detection of side effects, symptoms, and adverse reactions. Addison helps providers improve outcomes, strengthen coordination, and manage patient populations more effectively through a fully integrated RPM and CCM framework.
Addison is a lifelike 3D virtual caregiver interface that interacts naturally with patients to enhance daily adherence, monitor well-being, and connect seamlessly with healthcare teams. The platform enables:
Continuous oversight of patients between visits through AI-driven engagement, vitals tracking, and behavior analysis.
Early identification of health status changes, including side effects, response to prescribed treatment, or early signs of decline.
Streamlined coordination-connecting patient, provider, family, and TeleCare support in one unified ecosystem.
Turnkey implementation-from patient enrollment and logistics to technology provisioning, care delivery, and ongoing TeleCare management.
Customization for every provider-Addison programs are individually designed to align with each clinic’s workflows, staffing, and objectives, eliminating the “one-size-fits-all” approach.
This next-gen platform allows providers to scale RPM and CCM services efficiently, reduce clinical burden, and maintain proactive, personalized relationships with every patient in their care.
Quote from Leadership
“Primary care teams face enormous pressure balancing patient load, quality outcomes, and administrative complexity,” said Anthony Dohrmann, Founder and CEO of Electronic Caregiver. “Addison was designed to give those teams a lifelike, intelligent extension of their care delivery. It’s a 24/7 virtual teammate that never forgets a reminder, continuously monitors response to treatment, and connects providers, families, and patients in real time.
This isn’t a one-size-fits-all platform – it’s a fully customized solution, built around each provider’s exact workflow, staffing level, and patient needs. Addison brings together technology, TeleCare, logistics, and personalized support in one seamless system.”
Momentum from THRIVE and athenahealth Integration
Following its recent success at the athenahealth THRIVE Summit, Electronic Caregiver continues to strengthen partnerships across the primary care ecosystem. Addison’s interoperability with athenahealth and other leading EHR systems provides rapid deployment and bi-directional data flow, enabling:
Automated patient enrollment and remote monitoring activation
Real-time population analytics and intervention alerts
Streamlined monthly billing and care coordination workflows
Why the Summit Matters
The Annual Session & Primary Care Summit draws hundreds of family medicine physicians, clinical directors, and practice administrators from across Texas. With an estimated 30-40% of attendees using or familiar with the athenahealth platform, ECG’s exhibit offers a direct connection for providers seeking to modernize their RPM and CCM delivery models.
Primary-care teams visiting the booth will gain access to hands-on demonstrations and learn how Addison supports improved adherence, earlier detection, and better outcomes without adding administrative burden.
Live Demonstrations & Provider Consultations
At Booth #223, attendees will experience:
Addison’s 3D interactive Virtual Care Companion in real-time patient simulations
Multi-level integration options, including athenahealth and EHR-neutral workflows
Data dashboards showcasing adherence improvements and early intervention alerts
The Addison Care Launch Program, a turnkey path to implementation and reimbursement within 90 days
Visitors will also receive complimentary access to ECG’s Virtual Care Playbook for Primary Care Providers, outlining how practices can achieve measurable results in adherence, outcomes, and care coordination through the Addison platform.
About Electronic Caregiver
Electronic Caregiver, Inc., headquartered in Las Cruces, New Mexico, is an AI-driven health technology company serving healthcare organizations, providers, and consumers nationwide.
Its flagship innovation, Addison Care, is a human-like 3D virtual caregiver interface that delivers continuous engagement, vitals monitoring, adherence support, TeleCare coordination, and emergency response. Addison is powered by a HIPAA-compliant, AWS Well-Architected enterprise platform, integrated with major EHRs, and supported by a national 24/7 TeleCare Center staffed by trained specialists.
With over $140 million in research and development investment, 28 awarded and 50+ pending patents, and multiple certifications including FDA clearance and AWS Well-Architected Reviews, Electronic Caregiver stands at the forefront of scalable, intelligent, and compassionate virtual care.
About the Event
Annual Session & Primary Care Summit 2025 November 13-15, 2025 Renaissance Dallas Addison Hotel | Addison, TX Hosted by the Texas Academy of Family Physicians (TAFP) For event details, visit www.tafp.org/cme/aspcs
Media Contact
Travis Luevano Director, Digital Marketing media@ecg-hq.com (575) 649-7808
